<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clinicoecon Outcomes Res</journal-id><journal-title-group><journal-title>ClinicoEconomics and Outcomes Research: CEOR</journal-title></journal-title-group><issn pub-type="epub">1178-6981</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21935329</article-id><article-id pub-id-type="pmc">3169982</article-id><article-id pub-id-type="doi">10.2147/CEOR.S16118</article-id><article-id pub-id-type="publisher-id">ceor-3-019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mickisch</surname><given-names>Gerald HJ</given-names></name><xref ref-type="aff" rid="af1-ceor-3-019"><sup>1</sup></xref><xref ref-type="corresp" rid="c1-ceor-3-019"></xref></contrib><contrib contrib-type="author"><name><surname>Schwander</surname><given-names>Björn</given-names></name><xref ref-type="aff" rid="af2-ceor-3-019"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Escudier</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="af3-ceor-3-019"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellmunt</surname><given-names>Joaquim</given-names></name><xref ref-type="aff" rid="af4-ceor-3-019"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maroto</surname><given-names>José P</given-names></name><xref ref-type="aff" rid="af5-ceor-3-019"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Porta</surname><given-names>Camillo</given-names></name><xref ref-type="aff" rid="af6-ceor-3-019"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Walzer</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="af7-ceor-3-019"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Siebert</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="af8-ceor-3-019"><sup>8</sup></xref><xref ref-type="aff" rid="af9-ceor-3-019"><sup>9</sup></xref></contrib></contrib-group><aff id="af1-ceor-3-019"><label>1</label>Department of Urology, Center of Operative Urology Bremen, Bremen, Germany;</aff><aff id="af2-ceor-3-019"><label>2</label>Department of Outcomes Research, AiM GmbH Assessment-in-Medicine, Lörrach, Germany;</aff><aff id="af3-ceor-3-019"><label>3</label>Immunotherapy Unit, Institut Gustave Roussy, Villejuif, France;</aff><aff id="af4-ceor-3-019"><label>4</label>Department of Medical Oncology, University Hospital del Mar UPF, Barcelona, Spain;</aff><aff id="af5-ceor-3-019"><label>5</label>Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;</aff><aff id="af6-ceor-3-019"><label>6</label>Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy;</aff><aff id="af7-ceor-3-019"><label>7</label>Global Health Economics, F Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland;</aff><aff id="af8-ceor-3-019"><label>8</label>Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria;</aff><aff id="af9-ceor-3-019"><label>9</label>Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA</aff><author-notes><corresp id="c1-ceor-3-019">Correspondence: Gerald HJ Mickisch, Center of Operative Urology Bremen, Robert-Koch-Str 34a, 28277 Bremen, Germany, Tel +49 421 8700300, Fax +49 421 8700309, Email <email>gerald.mickisch@coub.de</email></corresp></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>25</day><month>1</month><year>2011</year></pub-date><volume>3</volume><fpage>19</fpage><lpage>27</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>© 2011 Mickisch et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2011</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4771" xml_f="4782" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4793" xml_f="5306" txt_i="23" txt_f="536">The vascular endothelial growth factor inhibitor bevacizumab (BEV) given in combination with interferon-α-2a (IFN), and the tyrosine kinase inhibitors (TKIs) sunitinib (SUN) and pazopanib (PAZ), have all shown significant increase in progression-free survival (PFS) in first-line metastatic renal-cell carcinoma (mRCC) therapy. These targeted therapies are currently competing to be primary choice; hence, in the absence of direct head-to-head comparison, there is a need for valid indirect comparison assessment.</offsets></p></sec><sec><title><offsets xml_i="5328" xml_f="5336" txt_i="538" txt_f="546">Methods:</offsets></title><p><offsets xml_i="5347" xml_f="5917" txt_i="547" txt_f="1117">Standard indirect comparison methods were applied to independent review PFS data of the pivotal Phase III trials, to determine indirect treatment comparison hazard-ratios (HR) with 95% confidence intervals (95% CI). As BEV+IFN and SUN have been compared to IFN, indirect comparison was enabled by the common IFN comparator arms. As PAZ was compared to placebo (PLA), a connector trial (IFN vs PLA) was required for the indirect comparison to BEV+IFN. Sensitivity analyses taking into account real-life influence of patient compliance on clinical outcomes were performed.</offsets></p></sec><sec><title><offsets xml_i="5939" xml_f="5947" txt_i="1119" txt_f="1127">Results:</offsets></title><p><offsets xml_i="5958" xml_f="6097" txt_i="1128" txt_f="1267">The indirect efficacy comparison resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (HR: 1.06; 95% CI: 0.78–1.45; </offsets><italic><offsets xml_i="6105" xml_f="6106" txt_i="1267" txt_f="1268">P</offsets></italic><offsets xml_i="6115" xml_f="6205" txt_i="1268" txt_f="1358"> = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; HR: 0.74–1.03; </offsets><italic><offsets xml_i="6213" xml_f="6214" txt_i="1358" txt_f="1359">P</offsets></italic><offsets xml_i="6223" xml_f="6394" txt_i="1359" txt_f="1530"> = 0.34–0.92). Simulating real-life patient compliance and its effectiveness impact showed an increased tendency towards BEV+IFN without reaching statistical significance.</offsets></p></sec><sec><title><offsets xml_i="6416" xml_f="6428" txt_i="1532" txt_f="1544">Conclusions:</offsets></title><p><offsets xml_i="6439" xml_f="6697" txt_i="1545" txt_f="1803">There is no statistically significant PFS difference between BEV+IFN and TKIs in first-line mRCC. These findings imply that additional treatment decision criteria such as tolerability and therapy sequencing need to be considered to guide treatment decisions.</offsets></p></sec></abstract><kwd-group><kwd>indirect treatment comparison</kwd><kwd>progression-free survival</kwd><kwd>renal cell carcinoma</kwd><kwd>bevacizumab</kwd><kwd>sunitinib</kwd><kwd>pazopanib</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="6951" xml_f="6963" txt_i="1812" txt_f="1824">Introduction</offsets></title><p><offsets xml_i="6974" xml_f="7072" txt_i="1825" txt_f="1923">Metastatic renal-cell carcinoma (mRCC) has always been one of the most drug-resistant malignancies</offsets><xref ref-type="bibr" rid="b1-ceor-3-019"><offsets xml_i="7114" xml_f="7115" txt_i="1923" txt_f="1924">1</offsets></xref><offsets xml_i="7122" xml_f="7212" txt_i="1924" txt_f="2014"> and the 5-year survival rates remain low at only around 10% and had not improved by 2008.</offsets><xref ref-type="bibr" rid="b2-ceor-3-019"><offsets xml_i="7254" xml_f="7255" txt_i="2014" txt_f="2015">2</offsets></xref><offsets xml_i="7262" xml_f="7263" txt_i="2015" txt_f="2016">,</offsets><xref ref-type="bibr" rid="b3-ceor-3-019"><offsets xml_i="7305" xml_f="7306" txt_i="2016" txt_f="2017">3</offsets></xref></p><p><offsets xml_i="7320" xml_f="7449" txt_i="2018" txt_f="2147">Over the past two decades, immunomodulating drugs such as interferon-α-2a (IFN) have been the standard first-line mRCC treatment,</offsets><xref ref-type="bibr" rid="b4-ceor-3-019"><offsets xml_i="7491" xml_f="7492" txt_i="2147" txt_f="2148">4</offsets></xref><offsets xml_i="7499" xml_f="7568" txt_i="2148" txt_f="2217"> and have been considered the standard comparator in clinical trials.</offsets><xref ref-type="bibr" rid="b5-ceor-3-019"><offsets xml_i="7610" xml_f="7611" txt_i="2217" txt_f="2218">5</offsets></xref><offsets xml_i="7618" xml_f="7886" txt_i="2218" txt_f="2486"> Recent advances in understanding the molecular biology of kidney cancer have resulted in the development of drugs that target known molecular pathways which are believed to be important in this disease, such as vascular endothelial growth factors and their receptors.</offsets></p><p><offsets xml_i="7893" xml_f="8446" txt_i="2487" txt_f="3040">The vascular endothelial growth factor inhibitor bevacizumab (BEV) given in combination with IFN, and the tyrosine kinase inhibitors (TKIs) sunitinib (SUN) and pazopanib (PAZ), have all shown significant increase in progression-free survival (PFS) in first-line mRCC therapy. These targeted therapies are currently competing to be the primary choice for the first-line therapy of mRCC patients presenting a good or intermediate prognosis. Hence, in the absence of direct head-to-head comparison, there is a need for valid indirect comparison assessment.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="8497" xml_f="8517" txt_i="3042" txt_f="3062">Material and methods</offsets></title><sec><title><offsets xml_i="8537" xml_f="8559" txt_i="3063" txt_f="3085">Pivotal trial outcomes</offsets></title><p><offsets xml_i="8570" xml_f="8822" txt_i="3086" txt_f="3338">The published Phase III pivotal trial PFS outcomes have been selected as the basis of the indirect treatment comparison (ITC), as these present the highest quality data based on independent central review assessment. Within these pivotal trials BEV+IFN</offsets><xref ref-type="bibr" rid="b6-ceor-3-019"><offsets xml_i="8864" xml_f="8865" txt_i="3338" txt_f="3339">6</offsets></xref><offsets xml_i="8872" xml_f="8880" txt_i="3339" txt_f="3347"> and SUN</offsets><xref ref-type="bibr" rid="b7-ceor-3-019"><offsets xml_i="8922" xml_f="8923" txt_i="3347" txt_f="3348">7</offsets></xref><offsets xml_i="8930" xml_f="9087" txt_i="3348" txt_f="3505"> have each shown a significant increase in PFS vs IFN in first-line mRCC therapy, whereas PAZ has shown a significant PFS increase compared to placebo (PLA),</offsets><xref ref-type="bibr" rid="b8-ceor-3-019"><offsets xml_i="9129" xml_f="9130" txt_i="3505" txt_f="3506">8</offsets></xref><offsets xml_i="9137" xml_f="9150" txt_i="3506" txt_f="3519"> as shown in </offsets><xref ref-type="fig" rid="f1-ceor-3-019"><offsets xml_i="9191" xml_f="9199" txt_i="3519" txt_f="3527">Figure 1</offsets></xref><offsets xml_i="9206" xml_f="9207" txt_i="3527" txt_f="3528">.</offsets></p><p><offsets xml_i="9214" xml_f="9383" txt_i="3529" txt_f="3698">The PFS hazard ratios (HRs) were selected as the preferred outcome for the ITC, as this effect measure accounts for censoring and incorporates time to event information.</offsets><xref ref-type="bibr" rid="b9-ceor-3-019"><offsets xml_i="9425" xml_f="9426" txt_i="3698" txt_f="3699">9</offsets></xref></p><p><offsets xml_i="9440" xml_f="9543" txt_i="3700" txt_f="3803">The independent review PFS HR of BEV+IFN vs IFN is 0.57 (95% confidence intervals [95% CI]: 0.45–0.72; </offsets><italic><offsets xml_i="9551" xml_f="9552" txt_i="3803" txt_f="3804">P</offsets></italic><offsets xml_i="9561" xml_f="9575" txt_i="3804" txt_f="3815"> &lt; 0.0001),</offsets><xref ref-type="bibr" rid="b6-ceor-3-019"><offsets xml_i="9617" xml_f="9618" txt_i="3815" txt_f="3816">6</offsets></xref><offsets xml_i="9625" xml_f="9679" txt_i="3816" txt_f="3870"> the PFS HR of SUN vs IFN is 0.54 (95% CI: 0.44–0.66; </offsets><italic><offsets xml_i="9687" xml_f="9688" txt_i="3870" txt_f="3871">P</offsets></italic><offsets xml_i="9697" xml_f="9711" txt_i="3871" txt_f="3882"> &lt; 0.00001)</offsets><xref ref-type="bibr" rid="b7-ceor-3-019"><offsets xml_i="9753" xml_f="9754" txt_i="3882" txt_f="3883">7</offsets></xref><offsets xml_i="9761" xml_f="9819" txt_i="3883" txt_f="3941"> and the PFS HR of PAZ vs PLA is 0.40 (95% CI: 0.27–0.60; </offsets><italic><offsets xml_i="9827" xml_f="9828" txt_i="3941" txt_f="3942">P</offsets></italic><offsets xml_i="9837" xml_f="9850" txt_i="3942" txt_f="3952"> &lt; 0.001),</offsets><xref ref-type="bibr" rid="b8-ceor-3-019"><offsets xml_i="9892" xml_f="9893" txt_i="3952" txt_f="3953">8</offsets></xref><offsets xml_i="9900" xml_f="9914" txt_i="3953" txt_f="3967"> respectively.</offsets></p><p><offsets xml_i="9921" xml_f="10245" txt_i="3968" txt_f="4292">The BEV+IFN study named AVOREN and the SUN trial focused on treatment-naïve mRCC patients (first-line population), whereas the PAZ study included both treatment-naïve and pretreated mRCC patients. Hence for the ITC the pazopanib results of treatment-naïve patients have been applied, based on prespecified subgroup analysis.</offsets></p><p><offsets xml_i="10252" xml_f="10264" txt_i="4293" txt_f="4305">As shown in </offsets><xref ref-type="table" rid="t1-ceor-3-019"><offsets xml_i="10307" xml_f="10314" txt_i="4305" txt_f="4312">Table 1</offsets></xref><offsets xml_i="10321" xml_f="10499" txt_i="4312" txt_f="4490"> study designs, patient characteristics, enrolment criteria, and study measurements are comparable, but not identical, between the AVOREN trial, the SUN trial, and the PAZ study.</offsets></p><p><offsets xml_i="10506" xml_f="11278" txt_i="4491" txt_f="5263">AVOREN and the PAZ trial were double-blinded placebo-controlled randomized trials, whereas the SUN study was a randomized open-label study. Furthermore, within the AVOREN trial 100% of patients were neph-rectomized (inclusion criteria) whereas in the SUN and the PAZ trial 88%–91% of patients had a previous nephrectomy. Another difference is that the SUN and the PAZ trials included more patients with a favorable prognosis (MSKCC risk score 0: 34%–39%) compared to the AVOREN study (27%–29%). Although both factors are regarded as predictive for the PFS outcome, the between-study differences are small, hence performing an indirect treatment comparison (ITC), without applying adjustments for patient characteristics variations, was regarded as an appropriate approach.</offsets></p></sec><sec><title><offsets xml_i="11300" xml_f="11338" txt_i="5265" txt_f="5303">Indirect treatment comparison approach</offsets></title><p><offsets xml_i="11349" xml_f="11502" txt_i="5304" txt_f="5457">The indirect treatment comparison of PFS outcomes of BEV+IFN vs SUN and vs PAZ uses the most widely applied indirect comparison approach by Bucher et al.</offsets><xref ref-type="bibr" rid="b12-ceor-3-019"><offsets xml_i="11545" xml_f="11547" txt_i="5457" txt_f="5459">12</offsets></xref><offsets xml_i="11554" xml_f="11611" txt_i="5459" txt_f="5516"> The Canadian Agency for Drugs and Technologies in Health</offsets><xref ref-type="bibr" rid="b13-ceor-3-019"><offsets xml_i="11654" xml_f="11656" txt_i="5516" txt_f="5518">13</offsets></xref><offsets xml_i="11663" xml_f="11674" txt_i="5518" txt_f="5529"> and others</offsets><xref ref-type="bibr" rid="b14-ceor-3-019"><offsets xml_i="11717" xml_f="11719" txt_i="5529" txt_f="5531">14</offsets></xref><offsets xml_i="11726" xml_f="11727" txt_i="5531" txt_f="5532">,</offsets><xref ref-type="bibr" rid="b15-ceor-3-019"><offsets xml_i="11770" xml_f="11772" txt_i="5532" txt_f="5534">15</offsets></xref><offsets xml_i="11779" xml_f="11925" txt_i="5534" txt_f="5680"> have recently identified this method as the most suitable approach for performing indirect treatment comparisons of randomized controlled trials.</offsets></p><p><offsets xml_i="11932" xml_f="12135" txt_i="5681" txt_f="5884">As BEV+IFN and SUN have been compared to IFN, indirect comparison was enabled by the common IFN control arms, whereas for comparing BEV+IFN vs PAZ a connector trial (IFN vs PLA) is required, as shown in </offsets><xref ref-type="fig" rid="f2-ceor-3-019"><offsets xml_i="12176" xml_f="12184" txt_i="5884" txt_f="5892">Figure 2</offsets></xref><offsets xml_i="12191" xml_f="12192" txt_i="5892" txt_f="5893">.</offsets></p><p><offsets xml_i="12199" xml_f="12765" txt_i="5894" txt_f="6460">For the identification of suitable connector trials a systematic literature search was performed using the following literature databases: PubMed, Embase, and Cochrane Central Register of Controlled Trials. As a result only three IFN studies have been identified that provided a suitable PFS HR compared to the Phase III trial outcomes (median PFS of IFN ≈ 5 months and median PFS for PLA ≈ 3 months) in treatment-naïve mRCC patients. Although none of these compared IFN vs PLA, the selected studies compared IFN regimens either to placebo-like therapy (MRCRCC trial</offsets><xref ref-type="bibr" rid="b16-ceor-3-019"><offsets xml_i="12808" xml_f="12810" txt_i="6460" txt_f="6462">16</offsets></xref><offsets xml_i="12817" xml_f="12891" txt_i="6462" txt_f="6536">) or to other IFN regimens that had a placebo-like PFS outcome (Aass et al</offsets><xref ref-type="bibr" rid="b17-ceor-3-019"><offsets xml_i="12934" xml_f="12936" txt_i="6536" txt_f="6538">17</offsets></xref><offsets xml_i="12943" xml_f="12962" txt_i="6538" txt_f="6557"> and Mickisch et al</offsets><xref ref-type="bibr" rid="b18-ceor-3-019"><offsets xml_i="13005" xml_f="13007" txt_i="6557" txt_f="6559">18</offsets></xref><offsets xml_i="13014" xml_f="13247" txt_i="6559" txt_f="6792">). In the absence of a valid IFN vs PLA connector trial all of these studies have been used to perform the ITC of BEV+IFN vs PAZ. Furthermore a PFS HR was estimated (‘proxy comparison’) based on the median PFS time of IFN (5.4 months</offsets><xref ref-type="bibr" rid="b6-ceor-3-019"><offsets xml_i="13289" xml_f="13290" txt_i="6792" txt_f="6793">6</offsets></xref><offsets xml_i="13297" xml_f="13325" txt_i="6793" txt_f="6821">) and of placebo (2.8 months</offsets><xref ref-type="bibr" rid="b8-ceor-3-019"><offsets xml_i="13367" xml_f="13368" txt_i="6821" txt_f="6822">8</offsets></xref><offsets xml_i="13375" xml_f="13526" txt_i="6822" txt_f="6973">) by assuming constant hazards (HR IFN vs PLA = 2.8 m/5.4 m = 0.52). The selected connector trials and the PFS HRs applied for IFN vs PLA are shown in </offsets><xref ref-type="table" rid="t2-ceor-3-019"><offsets xml_i="13569" xml_f="13576" txt_i="6973" txt_f="6980">Table 2</offsets></xref><offsets xml_i="13583" xml_f="13584" txt_i="6980" txt_f="6981">.</offsets></p><p><offsets xml_i="13591" xml_f="13691" txt_i="6982" txt_f="7082">The indirect comparisons of BEV+IFN vs SUN and BEV+IFN vs PAZ were performed for two key scenarios:
</offsets><list list-type="order"><list-item><p><offsets xml_i="13729" xml_f="13808" txt_i="7082" txt_f="7161">Indirect efficacy comparison: comparison of the Phase III results as published.</offsets></p></list-item><list-item><p><offsets xml_i="13838" xml_f="13925" txt_i="7162" txt_f="7249">Indirect effectiveness assessment based on simulating the impact of patient compliance.</offsets></p></list-item></list></p><p><offsets xml_i="13955" xml_f="14047" txt_i="7251" txt_f="7343">For both scenarios the indirect comparison HR of BEV+IFN vs TKIs with 95% CIs are provided. </offsets><xref ref-type="fig" rid="f3-ceor-3-019"><offsets xml_i="14088" xml_f="14096" txt_i="7343" txt_f="7351">Figure 3</offsets></xref><offsets xml_i="14103" xml_f="14167" txt_i="7351" txt_f="7415"> shows the detailed calculation pathway defined by Bucher et al,</offsets><xref ref-type="bibr" rid="b12-ceor-3-019"><offsets xml_i="14210" xml_f="14212" txt_i="7415" txt_f="7417">12</offsets></xref><offsets xml_i="14219" xml_f="14260" txt_i="7417" txt_f="7458"> including the BEV+IFN vs SUN comparison.</offsets></p><p><offsets xml_i="14267" xml_f="14620" txt_i="7459" txt_f="7812">For the comparison of BEV+IFN vs PAZ the same methodology was applied, but two ITCs needed to be performed in contrast to the SUN comparison. In a first step, the ITC HR of PAZ vs IFN was calculated (using the published PAZ PFS HR and the connector trials’ PFS HR) and in a second step this ITC HR result was compared to the published PFS HR of BEV+IFN.</offsets></p><p><offsets xml_i="14627" xml_f="14762" txt_i="7813" txt_f="7948">All calculations have been performed in Excel 2003 (Microsoft, Redmond, WA). The ITC calculations can be reperformed using the ITC tool</offsets><xref ref-type="bibr" rid="b20-ceor-3-019"><offsets xml_i="14805" xml_f="14807" txt_i="7948" txt_f="7950">20</offsets></xref><offsets xml_i="14814" xml_f="14923" txt_i="7950" txt_f="8059"> available from the Canadian Agency for Drugs and Technologies in Health, which ensures maximum transparency.</offsets></p></sec></sec><sec><title><offsets xml_i="14951" xml_f="14969" txt_i="8062" txt_f="8080">Patient compliance</offsets></title><p><offsets xml_i="14980" xml_f="15113" txt_i="8081" txt_f="8214">As the TKIs, SUN and PAZ are oral medications that are self-administered by the patient and show a considerable adverse event profile</offsets><xref ref-type="bibr" rid="b7-ceor-3-019"><offsets xml_i="15155" xml_f="15156" txt_i="8214" txt_f="8215">7</offsets></xref><offsets xml_i="15163" xml_f="15164" txt_i="8215" txt_f="8216">,</offsets><xref ref-type="bibr" rid="b8-ceor-3-019"><offsets xml_i="15206" xml_f="15207" txt_i="8216" txt_f="8217">8</offsets></xref><offsets xml_i="15214" xml_f="15271" txt_i="8217" txt_f="8274">, compliance effects are expected in real-world settings.</offsets></p><p><offsets xml_i="15278" xml_f="15738" txt_i="8275" txt_f="8735">In order to estimate patient compliance under routine conditions, data obtained from IMS Health were used as the basis for the estimation. These data were obtained on the basis of 1869 Dutch mRCC patients treated with sunitinib. Physician records have been used in order to determine patient compliance at different points in time. According to these data the median SUN compliance rate at 3, 6, and 9 months of SUN therapy was 74%, 72%, and 71%, respectively.</offsets></p><p><offsets xml_i="15745" xml_f="16009" txt_i="8736" txt_f="9000">As there are currently no published data on PAZ patient compliance available, it was assumed that the compliance rates are comparable to SUN. We performed analyses using the conservative estimates of 90%, 80%, and 70% patient compliance for the TKIs, respectively.</offsets></p><p><offsets xml_i="16016" xml_f="16414" txt_i="9001" txt_f="9399">In order to simulate the compliance impact on the PFS of the TKIs an adjustment of the PFS HR was performed. As no clinical trial data are available that show the effectiveness impact of noncompliance, it was conservatively assumed that the PFS HR of noncompliant patients is ‘1’, which means the same efficacy as for IFN, and that the published Phase III efficacy refers to the compliant patients.</offsets></p><p><offsets xml_i="16421" xml_f="16556" txt_i="9400" txt_f="9535">The detailed steps taken to estimate the real-world effectiveness (adjusted TKI PFS HR), depending on patient compliance, are shown in </offsets><xref ref-type="fig" rid="f4-ceor-3-019"><offsets xml_i="16597" xml_f="16605" txt_i="9535" txt_f="9543">Figure 4</offsets></xref><offsets xml_i="16612" xml_f="16721" txt_i="9543" txt_f="9652">, using a 70% SUN patient compliance as an example. The same approach was applied for all scenarios analyzed.</offsets></p><p><offsets xml_i="16728" xml_f="17096" txt_i="9653" txt_f="10021">As BEV is infused intravenously, the patient either visits the physician to receive the injection or decides to stop therapy by not attending. Even though many patients self-administer the subcutaneous IFN injections (in combination with BEV), which might be a potential compliance issue, downdosing of IFN has been shown to improve tolerability and maintain efficacy.</offsets><xref ref-type="bibr" rid="b21-ceor-3-019"><offsets xml_i="17139" xml_f="17141" txt_i="10021" txt_f="10023">21</offsets></xref><offsets xml_i="17148" xml_f="17312" txt_i="10023" txt_f="10187"> Hence it was assumed that missing an IFN injection has a limited impact on the PFS HR of BEV+IFN, so no patient compliance impact on BEV+IFN therapy was simulated.</offsets></p></sec><sec><title><offsets xml_i="17334" xml_f="17341" txt_i="10189" txt_f="10196">Results</offsets></title><p><offsets xml_i="17352" xml_f="17395" txt_i="10197" txt_f="10240">The indirect efficacy comparison, shown in </offsets><xref ref-type="fig" rid="f5-ceor-3-019"><offsets xml_i="17436" xml_f="17444" txt_i="10240" txt_f="10248">Figure 5</offsets></xref><offsets xml_i="17451" xml_f="17563" txt_i="10248" txt_f="10360">, resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (ITC HR: 1.06; 95% CI: 0.78–1.45; </offsets><italic><offsets xml_i="17571" xml_f="17572" txt_i="10360" txt_f="10361">P</offsets></italic><offsets xml_i="17581" xml_f="17675" txt_i="10361" txt_f="10455"> = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; ITC HR: 0.74–1.03; </offsets><italic><offsets xml_i="17683" xml_f="17684" txt_i="10455" txt_f="10456">P</offsets></italic><offsets xml_i="17693" xml_f="17707" txt_i="10456" txt_f="10470"> = 0.34–0.92).</offsets></p><p><offsets xml_i="17714" xml_f="17899" txt_i="10471" txt_f="10656">For the BEV+IFN vs PAZ comparison the two extreme scenarios are based on the selected connector trials, whereby using the MRCRCC trial resulted in an ITC HR of 1.03 (95% CI: 0.61–1.74; </offsets><italic><offsets xml_i="17907" xml_f="17908" txt_i="10656" txt_f="10657">P</offsets></italic><offsets xml_i="17917" xml_f="18009" txt_i="10657" txt_f="10749"> = 0.92) and using the ‘proxy comparison’ resulted in an ITC HR of 0.74 (95% CI: 0.40–1.37; </offsets><italic><offsets xml_i="18017" xml_f="18018" txt_i="10749" txt_f="10750">P</offsets></italic><offsets xml_i="18027" xml_f="18036" txt_i="10750" txt_f="10759"> = 0.34).</offsets></p><p><offsets xml_i="18043" xml_f="18219" txt_i="10760" txt_f="10936">Simulating real-life patient compliance and its effectiveness impact on PFS showed an increased tendency towards BEV+IFN without reaching statistical significance, as shown in </offsets><xref ref-type="fig" rid="f6-ceor-3-019"><offsets xml_i="18260" xml_f="18268" txt_i="10936" txt_f="10944">Figure 6</offsets></xref><offsets xml_i="18275" xml_f="18276" txt_i="10944" txt_f="10945">.</offsets></p><p><offsets xml_i="18283" xml_f="18516" txt_i="10946" txt_f="11179">For the comparison of BEV+IFN vs PAZ simulations have been performed for the extreme scenarios, which means the connector trials producing the highest ITC HR (MRCRCC Trial) and the lowest ITC HR (proxy comparison) have been analyzed.</offsets></p></sec><sec><title><offsets xml_i="18538" xml_f="18548" txt_i="11181" txt_f="11191">Discussion</offsets></title><p><offsets xml_i="18559" xml_f="19080" txt_i="11192" txt_f="11713">Comparing the PFS efficacy and effectiveness of BEV+IFN vs the TKIs SUN and PAZ in first-line mRCC therapy failed to show a significant tendency in favor of one particular targeted therapy approach. Additionally, the influence of patient compliance on the PFS was investigated. This indirect effectiveness assessment indicates that the PFS outcomes with regard to TKIs might be lower in real-world settings. However the observed tendency towards a better effectiveness of BEV+IFN failed to reach statistical significance.</offsets></p><p><offsets xml_i="19087" xml_f="19523" txt_i="11714" txt_f="12150">The main limitation is that our findings are based on indirect evidence. Such an indirect treatment comparison has to be regarded as a complementary assessment to clinical trials, because it cannot substitute direct evidence. However, in the absence of any head-to-head comparison, the indirect treatment comparison approach should be regarded as the most valuable way of estimating treatment effects in a statistically accurate manner.</offsets></p><p><offsets xml_i="19530" xml_f="20610" txt_i="12151" txt_f="13231">Another limitation is that there is no matching connector trial available in order to determine an exact ITC hazard ratio for the comparison of BEV+IFN vs PAZ. The lack of an adequate connector trial, comparing IFN vs PLA, was overcome by using different but the most suitable IFN studies in order to enable a bridge to be built between the PAZ and the BEV+IFN PFS outcomes. Furthermore, an additional ‘proxy comparison’ was performed that is based on assuming constant hazards to estimate a HR of IFN vs PLA based on the available Phase III evidence. The authors would like to point out that the application of constant hazards should be performed very carefully but in this special case (no adequate connector trial available) it was decided to perform this analysis to test the credibility of the bridging trials’ HR on the ITC results. As no statistically significant difference was observed when comparing the PFS HR of BEV+IFN vs PAZ, irrespective of the connector trial used, the lack of an adequate bridging trial is regarded as having a limited impact on the ITC results.</offsets></p><p><offsets xml_i="20617" xml_f="21129" txt_i="13232" txt_f="13744">Another limitation is that data on patient compliance to TKIs are currently rare. We used IMS data, which refers to the Dutch health care system, to estimate the proportion of patients who show a limited compliance to TKI therapy. As there are no real world investigations available that determine the impact of patient compliance on the PFS, we used a conservative assumption. However, further research is required in order to evaluate a more accurate link between patient compliance and its impact on efficacy.</offsets></p><p><offsets xml_i="21136" xml_f="21679" txt_i="13745" txt_f="14288">Another aspect to be considered is the difference in patient characteristics between the pivotal trials used. According to the patient’s risk profile, the AVOREN study included fewer patients with a favorable disease prognosis; hence the PFS outcomes might be underestimated in comparison to SUN and PAZ. However, as all patients have been nephrectomized in the AVOREN trial, which is regarded as an indicator for a better disease prognosis, these small differences in prognostic patient characteristics are estimated to compensate each other.</offsets></p><p><offsets xml_i="21686" xml_f="21806" txt_i="14289" txt_f="14409">In the past there was a consensus that SUN and BEV+IFN are equally effective in terms of PFS in first-line mRCC therapy,</offsets><xref ref-type="bibr" rid="b22-ceor-3-019"><offsets xml_i="21849" xml_f="21851" txt_i="14409" txt_f="14411">22</offsets></xref><offsets xml_i="21858" xml_f="21923" txt_i="14411" txt_f="14476"> which is in line with our findings. However, recent publications</offsets><xref ref-type="bibr" rid="b23-ceor-3-019"><offsets xml_i="21966" xml_f="21968" txt_i="14476" txt_f="14478">23</offsets></xref><offsets xml_i="21975" xml_f="21976" txt_i="14478" txt_f="14479">,</offsets><xref ref-type="bibr" rid="b24-ceor-3-019"><offsets xml_i="22019" xml_f="22021" txt_i="14479" txt_f="14481">24</offsets></xref><offsets xml_i="22028" xml_f="22086" txt_i="14481" txt_f="14539"> raised doubts about this comparable efficacy. Both papers</offsets><xref ref-type="bibr" rid="b23-ceor-3-019"><offsets xml_i="22129" xml_f="22131" txt_i="14539" txt_f="14541">23</offsets></xref><offsets xml_i="22138" xml_f="22139" txt_i="14541" txt_f="14542">,</offsets><xref ref-type="bibr" rid="b24-ceor-3-019"><offsets xml_i="22182" xml_f="22184" txt_i="14542" txt_f="14544">24</offsets></xref><offsets xml_i="22191" xml_f="22323" txt_i="14544" txt_f="14676"> focused only on investigator-assessed PFS values and pooled BEV+IFN PFS outcomes from a strictly controlled pivotal Phase III trial</offsets><xref ref-type="bibr" rid="b10-ceor-3-019"><offsets xml_i="22366" xml_f="22368" txt_i="14676" txt_f="14678">10</offsets></xref><offsets xml_i="22375" xml_f="22412" txt_i="14678" txt_f="14715"> and an investigator-initiated trial.</offsets><xref ref-type="bibr" rid="b25-ceor-3-019"><offsets xml_i="22455" xml_f="22457" txt_i="14715" txt_f="14717">25</offsets></xref><offsets xml_i="22464" xml_f="22604" txt_i="14717" txt_f="14857"> As a result of this pooling, the efficacy of BEV+IFN was decreased on the basis of a lower PFS observed in the investigator-initiated trial</offsets><xref ref-type="bibr" rid="b25-ceor-3-019"><offsets xml_i="22647" xml_f="22649" txt_i="14857" txt_f="14859">25</offsets></xref><offsets xml_i="22656" xml_f="22696" txt_i="14859" txt_f="14899"> compared to the pivotal trial outcomes.</offsets><xref ref-type="bibr" rid="b10-ceor-3-019"><offsets xml_i="22739" xml_f="22741" txt_i="14899" txt_f="14901">10</offsets></xref></p><p><offsets xml_i="22755" xml_f="22885" txt_i="14902" txt_f="15032">In order to ensure comparability, it was expected that the authors would apply the same procedure for SUN, using the pivotal trial</offsets><xref ref-type="bibr" rid="b11-ceor-3-019"><offsets xml_i="22928" xml_f="22930" txt_i="15032" txt_f="15034">11</offsets></xref><offsets xml_i="22937" xml_f="23001" txt_i="15034" txt_f="15098"> and the first-line outcomes from the SUN expanded-access-study,</offsets><xref ref-type="bibr" rid="b26-ceor-3-019"><offsets xml_i="23044" xml_f="23046" txt_i="15098" txt_f="15100">26</offsets></xref><offsets xml_i="23053" xml_f="23054" txt_i="15100" txt_f="15101">,</offsets><xref ref-type="bibr" rid="b27-ceor-3-019"><offsets xml_i="23097" xml_f="23099" txt_i="15101" txt_f="15103">27</offsets></xref><offsets xml_i="23106" xml_f="23161" txt_i="15103" txt_f="15158"> but only the pivotal trial outcomes were used for SUN.</offsets></p><p><offsets xml_i="23168" xml_f="23537" txt_i="15159" txt_f="15528">An adequate indirect comparison approach should take into account pivotal trials performed under the same conditions to be comparable and use the highest quality data (independent radiology review of PFS). Hence our approach focused on the comparison of the pivotal Phase III trials, using the highest data quality, in order to ensure comparability of therapy outcomes.</offsets></p><p><offsets xml_i="23544" xml_f="23688" txt_i="15529" txt_f="15673">Our findings have been confirmed by another recently published indirect treatment comparison performed from the perspective of PAZ. McCann et al</offsets><xref ref-type="bibr" rid="b28-ceor-3-019"><offsets xml_i="23731" xml_f="23733" txt_i="15673" txt_f="15675">28</offsets></xref><offsets xml_i="23740" xml_f="24297" txt_i="15675" txt_f="16232"> concluded “that pazopanib demonstrates no reduction in efficacy compared to other approved angiogenesis inhibitors”, which is in line with our findings that say ‘there is no significant difference in first-line PFS outcomes between BEV+IFN and the TKIs SUN and PAZ’. As a consequence there is a need for other clinical decision criteria that might allow an adequate therapy selection in first-line mRCC patients. Possible guidance might be offered by aspects of available therapy sequencing options, sequential therapy outcomes, and by tolerability issues.</offsets><xref ref-type="bibr" rid="b29-ceor-3-019"><offsets xml_i="24340" xml_f="24342" txt_i="16232" txt_f="16234">29</offsets></xref></p><p><offsets xml_i="24356" xml_f="24520" txt_i="16235" txt_f="16399">For example there is evidence that BEV+IFN shows a better tolerability profile if indirectly compared to SUN, which also impacts the costs of managing side effects.</offsets><xref ref-type="bibr" rid="b30-ceor-3-019"><offsets xml_i="24563" xml_f="24565" txt_i="16399" txt_f="16401">30</offsets></xref><offsets xml_i="24572" xml_f="24573" txt_i="16401" txt_f="16402">,</offsets><xref ref-type="bibr" rid="b31-ceor-3-019"><offsets xml_i="24616" xml_f="24618" txt_i="16402" txt_f="16404">31</offsets></xref><offsets xml_i="24625" xml_f="24754" txt_i="16404" txt_f="16533"> In addition, there are first retrospective analyses indicating that BEV+IFN first-line enables effective subsequent TKI therapy,</offsets><xref ref-type="bibr" rid="b6-ceor-3-019"><offsets xml_i="24796" xml_f="24797" txt_i="16533" txt_f="16534">6</offsets></xref><offsets xml_i="24804" xml_f="24805" txt_i="16534" txt_f="16535">,</offsets><xref ref-type="bibr" rid="b32-ceor-3-019"><offsets xml_i="24848" xml_f="24850" txt_i="16535" txt_f="16537">32</offsets></xref><offsets xml_i="24857" xml_f="24963" txt_i="16537" txt_f="16643"> which may lead to improved patient outcomes, taking into account the complete sequence of mRCC therapies.</offsets><xref ref-type="bibr" rid="b33-ceor-3-019"><offsets xml_i="25006" xml_f="25008" txt_i="16643" txt_f="16645">33</offsets></xref><offsets xml_i="25015" xml_f="25016" txt_i="16645" txt_f="16646">,</offsets><xref ref-type="bibr" rid="b34-ceor-3-019"><offsets xml_i="25059" xml_f="25061" txt_i="16646" txt_f="16648">34</offsets></xref></p></sec><sec><title><offsets xml_i="25090" xml_f="25101" txt_i="16650" txt_f="16661">Conclusions</offsets></title><p><offsets xml_i="25112" xml_f="25414" txt_i="16662" txt_f="16964">In conclusion, in the light of the currently available evidence, there is no statistically significant PFS difference between BEV+IFN and TKIs in first-line mRCC therapy. In terms of patient compliance there is an efficacy tendency in favor of BEV+IFN, but this fails to reach statistical significance.</offsets></p><p><offsets xml_i="25421" xml_f="25606" txt_i="16965" txt_f="17150">These findings imply that other treatment decision criteria such as tolerability and therapy sequencing opportunities need to be considered in order to guide adequate therapy decisions.</offsets></p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>This work was funded by F Hoffmann-La Roche Pharmaceuticals AG.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ceor-3-019"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppin</surname><given-names>C</given-names></name><name><surname>Porzsolt</surname><given-names>F</given-names></name><name><surname>Awa</surname><given-names>A</given-names></name><name><surname>Kumpf</surname><given-names>J</given-names></name><name><surname>Coldman</surname><given-names>A</given-names></name><name><surname>Wilt</surname><given-names>T</given-names></name></person-group><article-title>Immunotherapy for advanced renal cell cancer</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><volume>3</volume><fpage>CD001425</fpage><pub-id pub-id-type="pmid">10908496</pub-id></element-citation></ref><ref id="b2-ceor-3-019"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Commission on Cancer, American Cancer Society. National Cancer Data Base (NCDB)</collab></person-group><year>2008</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.facs.org/cancer/ncdb/">http://www.facs.org/cancer/ncdb/</ext-link>. Accessed 2010 Dec 6.</comment></element-citation></ref><ref id="b3-ceor-3-019"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nese</surname><given-names>N</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Mallin</surname><given-names>K</given-names></name><name><surname>Ritchey</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name></person-group><article-title>Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base</article-title><source>Ann Diagn Pathol</source><year>2009</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19118775</pub-id></element-citation></ref><ref id="b4-ceor-3-019"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JA</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name></person-group><article-title>Recent progress in the management of advanced renal cell carcinoma</article-title><source>CA Cancer J Clin</source><year>2007</year><volume>57</volume><issue>2</issue><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">17392388</pub-id></element-citation></ref><ref id="b5-ceor-3-019"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickisch</surname><given-names>GH</given-names></name></person-group><article-title>Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma</article-title><source>Eur Urol</source><year>2003</year><volume>43</volume><issue>6</issue><fpage>670</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">12767369</pub-id></element-citation></ref><ref id="b6-ceor-3-019"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha-2a (IFN) in metastatic renal cell carcinoma (mRCC): Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2009 May 29–Jun 2</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>15S</issue><fpage>5020</fpage></element-citation></ref><ref id="b7-ceor-3-019"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>22</issue><fpage>3584</fpage><lpage>3590</lpage><pub-id pub-id-type="pmid">19487381</pub-id></element-citation></ref><ref id="b8-ceor-3-019"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>CN</given-names></name><name><surname>Davis</surname><given-names>ID</given-names></name><name><surname>Mardiak</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>6</issue><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">20100962</pub-id></element-citation></ref><ref id="b9-ceor-3-019"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>BS</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name></person-group><article-title>Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial</article-title><source>BMC Med Res Methodol</source><year>2010</year><volume>10</volume><fpage>54</fpage><pub-id pub-id-type="pmid">20537177</pub-id></element-citation></ref><ref id="b10-ceor-3-019"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Koralewski</surname><given-names>P</given-names></name><etal></etal></person-group><article-title></article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9605</issue><fpage>2103</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">18156031</pub-id></element-citation></ref><ref id="b11-ceor-3-019"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><etal></etal></person-group><article-title>Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2007 Jun 1–5</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>18S</issue><fpage>5024</fpage><pub-id pub-id-type="pmid">17971603</pub-id></element-citation></ref><ref id="b12-ceor-3-019"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucher</surname><given-names>HC</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name></person-group><article-title>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</article-title><source>J Clin Epidemiol</source><year>1997</year><volume>50</volume><issue>6</issue><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">9250266</pub-id></element-citation></ref><ref id="b13-ceor-3-019"><label>13</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Sultan</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Coyle</surname><given-names>D</given-names></name></person-group><article-title>Indirect evidence: indirect treatment comparisons in meta-analysis</article-title><year>2009</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/884">http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/884</ext-link>. Accessed 2010 Dec 6.</comment></element-citation></ref><ref id="b14-ceor-3-019"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Glenny</surname><given-names>AM</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name></person-group><article-title>Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>326</volume><issue>7387</issue><fpage>472</fpage><pub-id pub-id-type="pmid">12609941</pub-id></element-citation></ref><ref id="b15-ceor-3-019"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tudur</surname><given-names>C</given-names></name><name><surname>Williamson</surname><given-names>PR</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Best</surname><given-names>LY</given-names></name></person-group><article-title>The value of the aggregate data approach in meta-analysis with time-to-event outcomes</article-title><source>J Royal Stat Soc</source><year>2002</year><volume>164</volume><issue>2</issue><fpage>357</fpage><lpage>370</lpage></element-citation></ref><ref id="b16-ceor-3-019"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Medical Research Council Renal Cancer Collaborators</collab></person-group><article-title>Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9146</issue><fpage>14</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10023944</pub-id></element-citation></ref><ref id="b17-ceor-3-019"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aass</surname><given-names>N</given-names></name><name><surname>de Mulder</surname><given-names>PH</given-names></name><name><surname>Mickisch</surname><given-names>GH</given-names></name><etal></etal></person-group><article-title>Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Group (EORTC 30951)</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>18</issue><fpage>4172</fpage><lpage>4178</lpage><pub-id pub-id-type="pmid">15961764</pub-id></element-citation></ref><ref id="b18-ceor-3-019"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickisch</surname><given-names>GH</given-names></name><name><surname>Garin</surname><given-names>A</given-names></name><name><surname>van</surname><given-names>PH</given-names></name><name><surname>de Prijck</surname><given-names>L</given-names></name><name><surname>Sylvester</surname><given-names>R</given-names></name></person-group><article-title>Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9286</issue><fpage>966</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">11583750</pub-id></element-citation></ref><ref id="b19-ceor-3-019"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Snedecor</surname><given-names>GW</given-names></name><name><surname>Cochran</surname><given-names>WG</given-names></name></person-group><article-title>Tests of hypotheses</article-title><source>Statistical Methods</source><edition>8th ed</edition><publisher-loc>Ames, IA</publisher-loc><publisher-name>Iowa State University Press</publisher-name><year>1989</year><fpage>64</fpage><lpage>82</lpage></element-citation></ref><ref id="b20-ceor-3-019"><label>20</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Sultan</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Coyle</surname><given-names>D</given-names></name></person-group><article-title>Indirect treatment comparison software application (version 1.0)</article-title><year>2009</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cadth.ca/index.php/en/itc-user-guide/download-software">http://www.cadth.ca/index.php/en/itc-user-guide/download-software</ext-link>. Accessed 2010 Jul 20.</comment></element-citation></ref><ref id="b21-ceor-3-019"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>B</given-names></name><name><surname>Koralewski</surname><given-names>P</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>8</issue><fpage>1470</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">18408224</pub-id></element-citation></ref><ref id="b22-ceor-3-019"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppin</surname><given-names>C</given-names></name><name><surname>Le</surname><given-names>L</given-names></name><name><surname>Porzsolt</surname><given-names>F</given-names></name><name><surname>Wilt</surname><given-names>T</given-names></name></person-group><article-title>Targeted therapy for advanced renal cell carcinoma</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>2</volume><fpage>CD006017</fpage><pub-id pub-id-type="pmid">18425931</pub-id></element-citation></ref><ref id="b23-ceor-3-019"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EJ</given-names></name><name><surname>Rachlis</surname><given-names>B</given-names></name><name><surname>O’Regan</surname><given-names>C</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Perri</surname><given-names>D</given-names></name></person-group><article-title>Metastatic renal cell cancer treatments: an indirect comparison meta-analysis</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>34</fpage><pub-id pub-id-type="pmid">19173737</pub-id></element-citation></ref><ref id="b24-ceor-3-019"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson Coon</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Hoyle</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness</article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><issue>2</issue><fpage>238</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">19568242</pub-id></element-citation></ref><ref id="b25-ceor-3-019"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>33</issue><fpage>5422</fpage><lpage>5428</lpage><pub-id pub-id-type="pmid">18936475</pub-id></element-citation></ref><ref id="b26-ceor-3-019"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2007 Jun 1–5</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>18S</issue><fpage>5010</fpage></element-citation></ref><ref id="b27-ceor-3-019"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">19615940</pub-id></element-citation></ref><ref id="b28-ceor-3-019"><label>28</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>O</given-names></name><name><surname>Pandite</surname><given-names>L</given-names></name><name><surname>Amado</surname><given-names>R</given-names></name></person-group><article-title>An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)</article-title><conf-name>Proceedings of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium</conf-name><conf-loc>San Francisco, CA</conf-loc><conf-date>2010 Mar 5–7</conf-date><comment>[Suppl; abstr # 413].</comment></element-citation></ref><ref id="b29-ceor-3-019"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Mulders</surname><given-names>P</given-names></name></person-group><article-title>Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma</article-title><source>Cancer Treat Rev</source><year>2010</year><volume>36</volume><issue>1</issue><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19819078</pub-id></element-citation></ref><ref id="b30-ceor-3-019"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Procopio</surname><given-names>G</given-names></name><name><surname>Verzoni</surname><given-names>E</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Costs of managing side effects in the treatment of first line metastatic renal cell carcinoma in Italy: Bevacizumab + Interferon alpha2a compared with Sunitinib: Proceedings of the European Society for Medical Oncology (ESMO) Congress, Stockholm, Sweden, 2008 Sep 12–16</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>8</issue><fpage>601P</fpage></element-citation></ref><ref id="b31-ceor-3-019"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickisch</surname><given-names>G</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Procopio</surname><given-names>G</given-names></name><name><surname>Walzer</surname><given-names>S</given-names></name><name><surname>Nuijten</surname><given-names>M</given-names></name></person-group><article-title>Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><issue>1</issue><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">19920817</pub-id></element-citation></ref><ref id="b32-ceor-3-019"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? Experience from AVOREN: Proceedings of the European Society for Medical Oncology (ESMO) Multidisciplinary Congress, Berlin, Germany, 2009 Sep 20–24</article-title><source>Eur J Cancer</source><year>2009</year><volume>7</volume><issue>2</issue><fpage>P7126</fpage></element-citation></ref><ref id="b33-ceor-3-019"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>B</given-names></name></person-group><article-title>How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?</article-title><source>Oncology</source><year>2009</year><volume>77</volume><issue>2</issue><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">19602908</pub-id></element-citation></ref><ref id="b34-ceor-3-019"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Goupil</surname><given-names>MG</given-names></name><name><surname>Massard</surname><given-names>C</given-names></name><name><surname>Fizazi</surname><given-names>K</given-names></name></person-group><article-title>Sequential therapy in renal cell carcinoma</article-title><source>Cancer</source><year>2009</year><volume>115</volume><issue>10 Suppl</issue><fpage>2321</fpage><lpage>2326</lpage><pub-id pub-id-type="pmid">19402067</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ceor-3-019" position="float"><label>Figure 1</label><caption><p>Pivotal Phase III progression-free survival outcomes in first-line mRCC therapy.</p><p><bold>Note:</bold> PAZ study results refer to the first-line sub-population.</p><p><bold>Abbreviations:</bold> AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; CI, confidence intervals; IFN, interferon-α-2a; HR, hazard ratio; PAZ, pazopanib; PFS, progression-free survival; PLA, placebo; SUN, sunitinib.</p></caption><graphic xlink:href="ceor-3-019f1"></graphic></fig><fig id="f2-ceor-3-019" position="float"><label>Figure 2</label><caption><p>Indirect treatment comparison: efficacy connections between the pivotal trials.</p><p><bold>Abbreviations:</bold> AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; IFN, interferon-α-2a; PLA, placebo; PAZ, pazopanib; RCT, randomized controlled trial.</p></caption><graphic xlink:href="ceor-3-019f2"></graphic></fig><fig id="f3-ceor-3-019" position="float"><label>Figure 3</label><caption><p>Indirect comparison methodology according to Bucher et al<xref ref-type="bibr" rid="b12-ceor-3-019">12</xref> showing the calculations for the comparison of BEV+IFN vs SUN.</p><p><bold>Notes:</bold> Starting with the published PFS HRs, study-specific log-hazard ratios are calculated (step 1) and transferred into an ITC HR (step 2); The indirect treatment comparison 95% confidence intervals are calculated using the 95% CI of the published PFS HR (steps 3–5).</p><p><bold>Abbreviations:</bold> BEV, bevacizumab; IFN, interferon-α-2a; ITC, indirect treatment comparison; SUN, sunitinib.</p></caption><graphic xlink:href="ceor-3-019f3"></graphic></fig><fig id="f4-ceor-3-019" position="float"><label>Figure 4</label><caption><p>Patient compliance PFS adjustment methodology.</p><p><bold>Abbreviations:</bold> HR, hazard ratio; IFN, interferon-α-2a; PFS, progression-free survival; SUN, sunitinib.</p></caption><graphic xlink:href="ceor-3-019f4"></graphic></fig><fig id="f5-ceor-3-019" position="float"><label>Figure 5</label><caption><p>Indirect efficacy comparison results PFS HR of BEV+IFN vs TKIs.</p><p><bold>Abbreviations:</bold> BEV, bevacizumab; IFN, interferon-α-2a; TKI, tyrosine kinase inhibitor; CI, confidence interval; HR, hazard ratio; SUN, sunitinib.</p></caption><graphic xlink:href="ceor-3-019f5"></graphic></fig><fig id="f6-ceor-3-019" position="float"><label>Figure 6</label><caption><p>Indirect effectiveness comparison results PFS HR of BEV+IFN vs TKIs.</p><p><bold>Abbreviations:</bold> BEV, bevacizumab; IFN, interferon-α-2a; HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; PAZ, pazopanib; MRCRCC, Medical Research Council Renal Cancer Collaborators.</p></caption><graphic xlink:href="ceor-3-019f6"></graphic></fig><table-wrap id="t1-ceor-3-019" position="float"><label>Table 1</label><caption><p>Comparison of the main study design, patient characteristics, enrolment criteria, and study measurements of the underlying pivotal trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th colspan="2" align="left" valign="top" rowspan="1">AVOREN study<xref ref-type="bibr" rid="b6-ceor-3-019">6</xref>,<xref ref-type="bibr" rid="b10-ceor-3-019">10</xref><hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1">SUN study<xref ref-type="bibr" rid="b7-ceor-3-019">7</xref>,<xref ref-type="bibr" rid="b11-ceor-3-019">11</xref><hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1">PAZ study<xref ref-type="bibr" rid="b8-ceor-3-019">8</xref><hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"></th><th align="left" valign="top" rowspan="1" colspan="1">BEV+IFN (n = 327)</th><th align="left" valign="top" rowspan="1" colspan="1">IFN (n = 322)</th><th align="left" valign="top" rowspan="1" colspan="1">SUN (n = 375)</th><th align="left" valign="top" rowspan="1" colspan="1">IFN (n = 375)</th><th align="left" valign="top" rowspan="1" colspan="1">PAZ (n = 290)</th><th align="left" valign="top" rowspan="1" colspan="1">PLA (n = 145)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"><hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1"><hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1"><hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1"><hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Study design</th><th colspan="2" align="left" valign="top" rowspan="1">Double-blinded placebo controlled RCT</th><th colspan="2" align="left" valign="top" rowspan="1">Open-label RCT</th><th colspan="2" align="left" valign="top" rowspan="1">Double-blinded placebo controlled RCT</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Immunotherapy-naïve (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">53%<xref ref-type="table-fn" rid="tfn2-ceor-3-019"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">54%<xref ref-type="table-fn" rid="tfn2-ceor-3-019"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nephrectomized (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">91%</td><td align="left" valign="top" rowspan="1" colspan="1">89%</td><td align="left" valign="top" rowspan="1" colspan="1">89%</td><td align="left" valign="top" rowspan="1" colspan="1">88%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clear-cell histology (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female (%)</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td><td align="left" valign="top" rowspan="1" colspan="1">28%</td><td align="left" valign="top" rowspan="1" colspan="1">32%</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median age (range)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (30–82)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (18–81)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (27–87)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (34–85)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (28–85)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (25–81)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSKCC risk score 0 (%)</td><td align="left" valign="top" rowspan="1" colspan="1">27%</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td><td align="left" valign="top" rowspan="1" colspan="1">38%</td><td align="left" valign="top" rowspan="1" colspan="1">34%</td><td align="left" valign="top" rowspan="1" colspan="1">39%</td><td align="left" valign="top" rowspan="1" colspan="1">39%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSKCC risk score 1–2 (%)</td><td align="left" valign="top" rowspan="1" colspan="1">56%</td><td align="left" valign="top" rowspan="1" colspan="1">56%</td><td align="left" valign="top" rowspan="1" colspan="1">56%</td><td align="left" valign="top" rowspan="1" colspan="1">59%</td><td align="left" valign="top" rowspan="1" colspan="1">55%</td><td align="left" valign="top" rowspan="1" colspan="1">53%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSKCC risk score ≥ 3 (%)</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">7%</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">7%</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSKCC risk score NA (%)</td><td align="left" valign="top" rowspan="1" colspan="1">9%</td><td align="left" valign="top" rowspan="1" colspan="1">7%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">3%</td><td align="left" valign="top" rowspan="1" colspan="1">4%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor assessment</td><td colspan="2" align="center" valign="top" rowspan="1">RECIST</td><td colspan="2" align="center" valign="top" rowspan="1">RECIST</td><td colspan="2" align="center" valign="top" rowspan="1">RECIST</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ceor-3-019"><p><bold>Note:</bold></p></fn><fn id="tfn2-ceor-3-019"><label>a</label><p>Patient characteristics refer to the overall population including therapy-naïve and pretreated patients however the PFS outcomes used in the ITC are based on the first-line (treatment-naïve) subpopulation.</p></fn><fn id="tfn3-ceor-3-019"><p><bold>Abbreviations:</bold> AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; IFN, interferon-α-2a; MSKCC, Memorial Sloan-Kettering Cancer Center; NA, not available; PAZ, pazopanib; PFS, progression-free survival; PLA, placebo; RCT, randomized controlled trial; RECIST, Response Evaluation Criteria in Solid Tumors; SUN, sunitinib.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ceor-3-019" position="float"><label>Table 2</label><caption><p>Overview of selected connector trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Author</th><th align="left" valign="top" rowspan="2" colspan="1">Year</th><th align="left" valign="top" rowspan="2" colspan="1">Comparison</th><th align="left" valign="top" rowspan="2" colspan="1">Total N</th><th colspan="2" align="left" valign="top" rowspan="1">Median PFS in months
<hr></hr></th><th align="left" valign="top" rowspan="2" colspan="1">PFS HR (95% CI)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">IFN<xref ref-type="table-fn" rid="tfn5-ceor-3-019"><sup>a</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">PLA<xref ref-type="table-fn" rid="tfn5-ceor-3-019"><sup>a</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MRCRCC trial<xref ref-type="bibr" rid="b16-ceor-3-019">16</xref></td><td align="left" valign="top" rowspan="1" colspan="1">1999</td><td align="left" valign="top" rowspan="1" colspan="1">IFN vs MPA</td><td align="left" valign="top" rowspan="1" colspan="1">335</td><td align="left" valign="top" rowspan="1" colspan="1">4.0</td><td align="left" valign="top" rowspan="1" colspan="1">3.0</td><td align="left" valign="top" rowspan="1" colspan="1">0.72 (0.56–0.92)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aass et al<xref ref-type="bibr" rid="b17-ceor-3-019">17</xref></td><td align="left" valign="top" rowspan="1" colspan="1">2005</td><td align="left" valign="top" rowspan="1" colspan="1">IFN plus 13-CRA vs IFN</td><td align="left" valign="top" rowspan="1" colspan="1">320</td><td align="left" valign="top" rowspan="1" colspan="1">5.1</td><td align="left" valign="top" rowspan="1" colspan="1">3.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.66 (0.52–0.85)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mickisch et al<xref ref-type="bibr" rid="b18-ceor-3-019">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">2001</td><td align="left" valign="top" rowspan="1" colspan="1">IFN plus nephrectomy vs IFN</td><td align="left" valign="top" rowspan="1" colspan="1">84</td><td align="left" valign="top" rowspan="1" colspan="1">5.8<xref ref-type="table-fn" rid="tfn6-ceor-3-019"><sup>b</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">3.4<xref ref-type="table-fn" rid="tfn6-ceor-3-019"><sup>b</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.60 (0.36–0.97)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proxy comparison</td><td align="left" valign="top" rowspan="1" colspan="1">2009</td><td align="left" valign="top" rowspan="1" colspan="1">IFN vs PLA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">5.4</td><td align="left" valign="top" rowspan="1" colspan="1">2.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.52<xref ref-type="table-fn" rid="tfn7-ceor-3-019"><sup>c</sup></xref>(0.32–0.72)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ceor-3-019"><p><bold>Notes:</bold></p></fn><fn id="tfn5-ceor-3-019"><label>a</label><p>Estimated median PFS for IFN and PLA, respectively;</p></fn><fn id="tfn6-ceor-3-019"><label>b</label><p>Median time to progression;</p></fn><fn id="tfn7-ceor-3-019"><label>c</label><p>Estimated HR based on Phase III median PFS outcomes<xref ref-type="bibr" rid="b6-ceor-3-019">6</xref>,<xref ref-type="bibr" rid="b8-ceor-3-019">8</xref> assuming constant hazards.</p></fn><fn id="tfn8-ceor-3-019"><p><bold>Abbreviations:</bold> 13-CRA, 13-cis-retinoic acid; HR, hazard ratio; IFN, interferon-α-2a; MPA, medroxy-progesterone acetate; MRCRCC, Medical Research Council Renal Cancer Collaborators; NA, not available; PLA, placebo; PFS, progression-free survival.</p></fn></table-wrap-foot></table-wrap></floats-group></article>